Advanced Practice Providers

Burnout

Concierge Medicine

Concierge Medicine 2.0 by Castle Connolly Private Health Partners

Employment Trends

Learning and Development

Locum Tenens, brought to you by LocumLife®

Maintenance of Certification

Careers

Contract Negotiation

Insurance

Malpractice

Risk Management

Legal

Opinion

Estate Planning

Investing

Retirement Planning

Physician's Money Digest

Industry Trends

Medicare & Medicaid

Pharma Industry

Physician Advocacy

Politics

Policy

Billing and Collections

Payment Models

Practice Valuation

Practice valuation

Reimbursement

Revenue Cycle Management

Practice Finance

Chronic Condition Management

Coding and Documentation

Leadership

Marketing

Patient Relations

Staffing

Vaccines

Practice Management

100 Years of Medical Economics

Exclusive Content 

Special Reports

Cybersecurity

EHRs

Medical Technology

Remote Patient Monitoring

Telehealth

Technology

News

All News

Money

Physicians Financial News

Media

Around the Practice

Between The Lines

Clinical Consult

Expert Interviews

Medical Economics Pulse

Medical World News

Off The Charts Podcasts

Physician Report

PrimaryView

Academy

Conferences

Conference Coverage

Conference Listing

Publications

Medical Economics

Supplements And Featured Publications

CME/CE

Job Board

Subscribe

Directories

Financial Advisor Guide

Medical Economics is the leading health care business media brand for physicians, serving our audience of doctors through our print magazine, in-depth features, video interviews, podcasts and more.

About

Advertise

Contact Us

Editorial Staff

Terms and Conditions

Contributor Guidelines

Privacy Policy

Do Not Sell My Personal Information

Facebook

LinkedIn

Business Focus

Career Planning

Electronic Health Records

Personal Finance

Value-based Care

Locum Tenens

Clinical  Focus

Allergy and Immunology

Cardiology

Dermatology

Endocrinology

Gastroenterology

Infectious Disease

Neurology

Pain Management

Pediatrics

Psychiatry

Pulmonology

Rheumatology

Women's Health

Spotlight

The benefits of a physician MBA program

Physician Bootcamp

1rem

Topics

Health care organizations respond to ‘mixed bag’ bill.

Telehealth, PBM reforms part of House year-end spending plan

ACP also calls for action on prior authorizations.

Clock is ticking for 2024 action on Medicare physician reimbursement, PBM reforms

Ferguson, who opposed ban of noncompetes, named to succeed Chair Khan; new commissioner Meador called for PBM regulations.

FTC to get leadership change, new commissioner under Trump administration

PBMs are powerful middlemen that control prescription drug access for millions of Americans, and their business model is nefarious -- but currently legal.

Congress has a rare chance to lower drug prices

The regulatory battle over compounded semaglutide and health effects on the heart are among latest developments involving GLP-1 RA drugs.

Tirzepatide tops semaglutide for patient weight loss, study finds

GLP-1 RA antiobesity medications: an introduction

GLP-1 RA antiobesity medications: a new panacea?

GLP-1 RA antiobesity medications: Patients’ No. 1 question

GLP-1 RA antiobesity medications: Talking about cost

GLP-1 RA antiobesity medications: Lifestyle changes are needed too

GLP-1 RA antiobesity medications: Learning about side effects, and managing them

GLP-1 RA antiobesity medications: Long-term safety

GLP-1 RA antiobesity medications: Predictions for the future

The new glucagon-like peptide-1 receptor agonist (GLP-1 RA) antiobesity medications have taken medicine by storm.

, with manageable side effects and no indications yet of harmful long-term effects. 

 are clamoring for them. What do physicians think about these treatments?

, is the author or editor of 15 books, 65 book chapters and hundreds of scientific articles on overweight, obesity, nutrition, diet and exercise. He has traveled to dozens of countries speaking as an expert on those topics.

 about the effects these medicines are having, not just on BMI, but in physician and patient interactions around the country.

Look for his next book, “Patient Centered Weight Management: The Six Factor Professional Program & Toolkit,” written for medical and health care professionals, coming in 2025. It is the follow-up to his volume, “Six Factors to Fit: Weight Loss That Works for You!”

(And as the calendar winds down into the holiday season, here’s a bonus: 

 his blog with three tips physicians and patients can use to maintain healthy dietary habits in coming days.)

Videos

The introduction of new GLP-1 receptor agonist antiobesity medications has significantly impacted the medical field, offering effective BMI reduction with manageable side effects and no known long-term harm. These medications have generated high demand among patients, influencing physician-patient interactions nationwide. Dr. Robert Kushner, a renowned expert in obesity and nutrition, has extensively contributed to the literature on these topics. His upcoming book, "Patient Centered Weight Management," aims to provide healthcare professionals with a comprehensive program for weight management, following his previous work on effective weight loss strategies.

Robert Kushner, MD, an expert in overweight, obesity, nutrition, diet and exercise, discusses the effects of the new antiobesity medications.

Weight Management

GLP-1 RA drugs and primary care: What do physicians need to know?

GLP-1 RA drugs are an important step in changing the 

 in thinking about obesity, and new drugs will come in a relatively short period of time. Meanwhile, “the cost clearly has to come down,” said 

, an expert researcher and author about overweight, obesity and nutrition. He’s also a doctor who has treated patients for years through Northwestern University’s Feinberg School of Medicine and Northwestern Medicine’s Center for Lifestyle Medicine.

The development of GLP-1 receptor agonist (RA) drugs marks a significant advancement in obesity treatment, reflecting a paradigm shift in the perception of obesity management. Anticipation surrounds the introduction of new pharmacological options in the near future. However, the high cost of these treatments remains a critical issue that needs addressing. Dr. Robert Kushner, a leading researcher and clinician in obesity and nutrition, emphasizes the necessity for cost reduction to make these treatments more accessible to patients, drawing from his extensive experience at Northwestern University.

A physician researcher and author discusses the latest information on GLP-1 RA antiobesity medications.

 that could be life-changing in a good way for millions of patients. What if they cause 

 that becomes life-changing in a bad way? So far, that hasn’t happened, and while the drugs still are relatively new for weight loss, they have been used for years in diabetes treatment. 

, discussed the research. He has made a career as a researcher and author about overweight, obesity and nutrition. He’s also a doctor who has treated patients for years through Northwestern University’s Feinberg School of Medicine and Northwestern Medicine’s Center for Lifestyle Medicine.

Side effects play a role in a patient’s desire to use 

. Scientists studied the side effects in formal, controlled research that guides physicians when prescribing the drugs to patients. But real-world experiences may differ, and patients may not persist with a treatment regimen due to physical side effects. Cost and availability also play a role, said said 

. He has made a career as a researcher and author about overweight, obesity and nutrition. He’s also a doctor who has treated patients for years through Northwestern University’s Feinberg School of Medicine and Northwestern Medicine’s Center for Lifestyle Medicine.

Patients' willingness to use GLP-1 RA drugs for weight loss or other health conditions is influenced by side effects, which are studied in controlled research to guide physicians. However, real-world experiences may differ, leading to treatment discontinuation due to physical side effects. Cost and availability also impact patient adherence. Robert Kushner, MD, a researcher and clinician specializing in obesity and nutrition, emphasizes these factors. His extensive experience at Northwestern University’s Feinberg School of Medicine and Northwestern Medicine’s Center for Lifestyle Medicine informs his insights on patient treatment.

. He has made a career as a researcher and author about overweight, obesity and nutrition. He’s also a doctor who has treated patients for years through Northwestern University’s Feinberg School of Medicine and Northwestern Medicine’s Center for Lifestyle Medicine. His next book, “Patient Centered Weight Management: The Six Factor Professional Program & Toolkit,” written for medical and health care professionals, is due out in 2025, with his wife and co-author, Nancy Kushner, MSN, RN. It is the follow-up to his volume, “Six Factors to Fit: Weight Loss That Works for You!”

Lifestyle modifications are crucial when patients start using GLP-1 RA antiobesity drugs, according to Dr. Robert Kushner, a seasoned researcher and clinician in obesity and nutrition. Dr. Kushner emphasizes the integration of lifestyle changes with pharmacotherapy for effective weight management. His upcoming book, "Patient Centered Weight Management: The Six Factor Professional Program & Toolkit," aims to provide healthcare professionals with comprehensive strategies for patient-centered weight management. This work builds on his previous publication, "Six Factors to Fit: Weight Loss That Works for You!"

GLP-1 RA antiobesity medications: Lifestyle changes needed too

 are effective – and expensive. How should physicians talk about this with 

, discusses the financial factors that affect patient treatment for obesity. He has made a career as a researcher and author about overweight, obesity and nutrition. He’s also a doctor who has treated patients for years through Northwestern University’s Feinberg School of Medicine and Northwestern Medicine’s Center for Lifestyle Medicine.

The introduction of GLP-1 receptor agonists (RAs) has shown significant efficacy in obesity treatment, but their high cost presents a challenge for patient access. Physicians must navigate these financial barriers when discussing treatment options with patients. Dr. Robert Kushner, an expert in obesity and nutrition, emphasizes the importance of transparent communication regarding the financial implications of these medications. His extensive experience in both research and clinical practice at Northwestern University underscores the need for balancing effective treatment with patient affordability and accessibility.

. But there is a start to every conversation with their physician, nurse practitioner, or primary care provider, said 

, who has made a career as a researcher and author about overweight, obesity and nutrition. He’s also a doctor who has treated patients for years through Northwestern University’s Feinberg School of Medicine and Northwestern Medicine’s Center for Lifestyle Medicine.

Patients are increasingly curious about GLP-1 RA antiobesity medications, prompting essential discussions with healthcare providers. Dr. Robert Kushner, a seasoned researcher and clinician in obesity and nutrition, emphasizes the importance of initiating these conversations. With extensive experience at Northwestern University's Feinberg School of Medicine and the Center for Lifestyle Medicine, Dr. Kushner advocates for informed dialogue between patients and their healthcare providers. This approach aims to address patient concerns and enhance understanding of these medications' role in managing obesity effectively.

 in body mass index and overall health when they take the new 

. These drugs are not a cure-all, but they are effective and are shifting medicine to study the gut-brain axis and how it affects human health. Here’s an explanation by 

GLP-1 RA antiobesity medications are demonstrating efficacy in improving body mass index and overall health, though they are not a panacea. These drugs are prompting a shift in medical research towards understanding the gut-brain axis and its impact on human health. Robert Kushner, MD, a seasoned researcher and clinician in obesity and nutrition, provides insights into these developments. His extensive experience at Northwestern University’s Feinberg School of Medicine and Northwestern Medicine’s Center for Lifestyle Medicine underscores the significance of these advancements in obesity treatment.

 are showing excellent benefits for patient body mass index and health. 

, has made a career as a researcher and author about overweight, obesity and nutrition. He’s also a doctor who has treated patients for years through Northwestern University’s Feinberg School of Medicine and Northwestern Medicine’s Center for Lifestyle Medicine.

The introduction of GLP-1 receptor agonists (RAs) as antiobesity medications is demonstrating significant improvements in patient body mass index and overall health. These medications are gaining attention from patients eager to learn more about their benefits. Dr. Robert Kushner, a prominent researcher and clinician in the fields of obesity and nutrition, has been instrumental in advancing understanding and treatment of obesity. His work at Northwestern University’s Feinberg School of Medicine and the Center for Lifestyle Medicine has contributed to the development and application of these innovative therapies.

Congressional perspectives: PBM reforms

Rep. Buddy Carter (R-Georgia) discusses the Protecting Patients from PBM Abuses Act, which aims to 

 by regulating pharmacy benefit managers (PBMs).

Pharma Industry

Latest News